Hot-melt coating with lipid excipients.

V. Jannin,Y. Cuppok

DOI: https://doi.org/10.1016/j.ijpharm.2012.10.026

IF: 6.51

2013-12-05

International Journal of Pharmaceutics

Abstract:

What problem does this paper attempt to address?

Gaps in kidney stone disease management: From clinical theory to patient reality

Agnieszka Pozdzik,Viridiana Grillo,Khashayar Sakhaee

DOI: https://doi.org/10.1007/s00240-024-01563-6

2024-04-10

Urolithiasis

Abstract:With nephrolithiasis projected to affect 25% of the global population in the next three decades, there is an urgent call for innovative management strategies to prevent and reduce stone recurrence. This study aims to explore the evolving management needs in nephrolithiasis from both patient and healthcare provider perspectives. An expert-collaborative online survey comprising 10 targeted questions on kidney stone management was developed and disseminated. This survey was designed to gather comprehensive insights from patients, physicians and dietician and other person in the field of nephrolithiasis. Analysis of responses from 120 participants, including 45 nephrologists, 38 dieticians, 11 urologists, and 14 kidney stones patients followed in our hospital, revealed critical insights. A significant 97.5% emphasized the necessity of optimizing daily water intake, and 94.1% recognized the need for practical dietary modifications. Additionally, 88.3% of respondents found timely hydration reminders beneficial. Notably, monitoring urine color and pH was valued by 85% and 84.3% of the participants, respectively. A striking disparity emerged in the perception of fatigue and wellness monitoring, with 65% of patients prioritizing fatigue monitoring, a view less shared by healthcare professionals. Similarly, 71% of patients deemed wellness monitoring essential, highlighting a gap in understanding between patients and their caregivers. This study underscores the critical need for more tailored guidance on hydration strategies and the promise of remote urine parameters monitoring in nephrolithiasis management. The findings strongly advocate for a patient-centered approach, aligning medical recommendations with patient lifestyles and experiences, to enhance the effectiveness of nephrolithiasis management.

urology & nephrology
Research Priority Setting in Kidney Disease: A Systematic Review

Allison Tong,Shingisai Chando,Sally Crowe,Braden Manns,Wolfgang C. Winkelmayer,Brenda Hemmelgarn,Jonathan C. Craig

DOI: https://doi.org/10.1053/j.ajkd.2014.11.011

IF: 11.072

2015-05-01

American Journal of Kidney Diseases

Abstract:BACKGROUND: <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Resources for research are insufficient to cover all unanswered questions, and therefore difficult choices about allocation must be made. Recently there has been a move toward more patient-centered research. This study aims to evaluate approaches to research prioritization in kidney disease and describe research priorities of patients with kidney disease, their caregivers, the health care providers involved in their care, and policy makers.</AbstractText>STUDY DESIGN: <AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">Systematic review.</AbstractText>SETTING & POPULATION: <AbstractText Label="SETTING &amp; POPULATION" NlmCategory="METHODS">Studies that elicited patient, caregiver, health care provider, or policy maker priorities for research in kidney disease were included.</AbstractText>SEARCH STRATEGY & SOURCES: <AbstractText Label="SEARCH STRATEGY &amp; SOURCES" NlmCategory="METHODS">MEDLINE, EMBASE, PsycINFO, and CINAHL were searched to May 2014.</AbstractText>ANALYTICAL APPROACH: <AbstractText Label="ANALYTICAL APPROACH" NlmCategory="METHODS">Descriptive synthesis.</AbstractText>RESULTS: <AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 16 studies (n=2,365 participants) conducted in the United States, the Netherlands, Australia, Canada, and internationally. Only 4 (25%) studies explicitly involved patients. Various priority-setting methods were used, including the Delphi technique, expert panels, consensus conference, ranking or voting surveys, focus groups, and interviews, of which the process was described in detail by 11 (69%) studies. The priority areas for research most frequently identified across studies were prevention of acute kidney injury, prevention of chronic kidney disease progression, fluid and diet restrictions, improving vascular access, kidney transplant survival, access to transplantation, patient education, and psychosocial impact of chronic kidney disease.</AbstractText>LIMITATIONS: <AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Most studies were conducted in high-income countries.</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The priorities identified by kidney disease research priority-setting exercises are broad ranging, but patient involvement is uncommon and the processes often are incompletely described. Establishing research priorities using a prespecified and transparent process that engages patients, caregivers, and health care providers is needed to ensure that resources are invested to answer questions that address the shared priorities in kidney disease.</AbstractText>

urology & nephrology
Research directions for kidney stone disease

Vincent Blay,Felix Grases

2023-08-31

Abstract:Kidney stone disease poses a major burden to patients and healthcare systems around the world. The formation of kidney stones may occur over months or years, but many patients are diagnosed at a late stage, suffer excruciating pain, and require surgical intervention to physically remove the stones. The prevalence of kidney stones has increased during recent decades to over 10% in many developed countries, suggesting a link with environmental and behavioral factors. Recurrence rates are also high. In terms of their impact and scale, kidney stones are an ongoing pandemic. The causes and mechanisms of kidney stone formation are diverse and often unknown, resulting in varied compositions and different anatomical locations being affected. A better understanding of these processes could enable earlier diagnoses through more sensitive and scalable biomarkers, as well as more effective preventives and therapeutics.

Tissues and Organs
Clinical Trial Considerations in Developing Treatments for Early Stages of Common, Chronic Kidney Diseases: A Scientific Workshop Cosponsored by the National Kidney Foundation and the US Food and Drug Administration

Lesley A Inker,Morgan E Grams,Hrefna Guðmundsdóttir,Phil McEwan,Robert Friedman,Aliza Thompson,Daniel E Weiner,Kerry Willis,Hiddo J L Heerspink,NKF-FDA Conference on Clinical Trial Considerations in Developing Treatments for Early Stages of Common, Chronic Kidney Diseases Advisory Group,Dustin Little,Vivek Jha,Melissa West,Andrew S Levey,Michael Walsh,Amy K Mottl,Navdeep Tangri,Magdalena Madero,Uptal D Patel,Barbara S Gillespie,Deidra C Crews,Adeera Levin

DOI: https://doi.org/10.1053/j.ajkd.2022.03.011

Abstract:In the past decade, advances in the validation of surrogate end points for chronic kidney disease (CKD) progression have heightened interest in evaluating therapies in early CKD. In December 2020, the National Kidney Foundation sponsored a scientific workshop in collaboration with the US Food and Drug Administration (FDA) to explore patient, provider, and payor perceptions of the value of treating early CKD. The workshop reviewed challenges for trials in early CKD, including trial designs, identification of high-risk populations, and cost-benefit and safety considerations. Over 90 people representing a range of stakeholders including experts in clinical trials, nephrology, cardiology and endocrinology, patient advocacy organizations, patients, payors, health economists, regulators and policy makers attended a virtual meeting. There was consensus among the attendees that there is value to preventing the development and treating the progression of early CKD in people who are at high risk for progression, and that surrogate end points should be used to establish efficacy. Attendees also concluded that cost analyses should be holistic and include aspects beyond direct savings for treatment of kidney failure; and that safety data should be collected outside/beyond the duration of a clinical trial. Successful drug development and implementation of effective therapies will require collaboration across sponsors, patients, patient advocacy organizations, medical community, regulators, and payors.
Management of urinary stones: state of the art and future perspectives by experts in stone disease

Athanasios Papatsoris,Alberto Budia Alba,Juan Antonio Galán Llopis,Murtadha Al Musafer,Mohammed Alameedee,Hammad Ather,Juan Pablo Caballero-Romeu,Antònia Costa-Bauzá,Athanasios Dellis,Mohamed El Howairis,Giovanni Gambaro,Bogdan Geavlete,Adam Halinski,Bernhard Hess,Syed Jaffry,Dirk Kok,Hichem Kouicem,Luis Llanes,Juan M Lopez Martinez,Elenko Popov,Allen Rodgers,Federico Soria,Kyriaki Stamatelou,Alberto Trinchieri,Christian Tuerk

DOI: https://doi.org/10.4081/aiua.2024.12703

2024-06-27

Abstract:Aim: To present state of the art on the management of urinary stones from a panel of globally recognized urolithiasis experts who met during the Experts in Stone Disease Congress in Valencia in January 2024. Options of treatment: The surgical treatment modalities of renal and ureteral stones are well defined by the guidelines of international societies, although for some index cases more alternative options are possible. For 1.5 cm renal stones, both m-PCNL and RIRS have proven to be valid treatment alternatives with comparable stone-free rates. The m-PCNL has proven to be more cost effective and requires a shorter operative time, while the RIRS has demonstrated lower morbidity in terms of blood loss and shorter recovery times. SWL has proven to be less effective at least for lower calyceal stones but has the highest safety profile. For a 6mm obstructing stone of the pelviureteric junction (PUJ) stone, SWL should be the first choice for a stone less than 1 cm, due to less invasiveness and lower risk of complications although it has a lower stone free-rate. RIRS has advantages in certain conditions such as anticoagulant treatment, obesity, or body deformity. Technical issues of the surgical procedures for stone removal: In patients receiving antithrombotic therapy, SWL, PCN and open surgery are at elevated risk of hemorrhage or perinephric hematoma. URS, is associated with less morbidity in these cases. An individualized combined evaluation of risks of bleeding and thromboembolism should determine the perioperative thromboprophylactic strategy. Pre-interventional urine culture and antibiotic therapy are mandatory although UTI treatment is becoming more challenging due to increasing resistance to routinely applied antibiotics. The use of an intrarenal urine culture and stone culture is recommended to adapt antibiotic therapy in case of postoperative infectious complications. Measurements of temperature and pressure during RIRS are vital for ensuring patient safety and optimizing surgical outcomes although techniques of measurements and methods for data analysis are still to be refined. Ureteral stents were improved by the development of new biomaterials, new coatings, and new stent designs. Topics of current research are the development of drug eluting and bioresorbable stents. Complications of endoscopic treatment: PCNL is considered the most invasive surgical option. Fever and sepsis were observed in 11 and 0.5% and need for transfusion and embolization for bleeding in 7 and 0.4%. Major complications, as colonic, splenic, liver, gall bladder and bowel injuries are quite rare but are associated with significant morbidity. Ureteroscopy causes less complications, although some of them can be severe. They depend on high pressure in the urinary tract (sepsis or renal bleeding) or application of excessive force to the urinary tract (ureteral avulsion or stricture). Diagnostic work up: Genetic testing consents the diagnosis of monogenetic conditions causing stones. It should be carried out in children and in selected adults. In adults, monogenetic diseases can be diagnosed by systematic genetic testing in no more than 4%, when cystinuria, APRT deficiency, and xanthinuria are excluded. A reliable stone analysis by infrared spectroscopy or X-ray diffraction is mandatory and should be associated to examination of the stone under a stereomicroscope. The analysis of digital images of stones by deep convolutional neural networks in dry laboratory or during endoscopic examination could allow the classification of stones based on their color and texture. Scanning electron microscopy (SEM) in association with energy dispersive spectrometry (EDS) is another fundamental research tool for the study of kidney stones. The combination of metagenomic analysis using Next Generation Sequencing (NGS) techniques and the enhanced quantitative urine culture (EQUC) protocol can be used to evaluate the urobiome of renal stone formers. Twenty-four hour urine analysis has a place during patient evaluation together with repeated measurements of urinary pH with a digital pH meter. Urinary supersaturation is the most comprehensive physicochemical risk factor employed in urolithiasis research. Urinary macromolecules can act as both promoters or inhibitors of stone formation depending on the chemical composition of urine in which they are operating. At the moment, there are no clinical applications of macromolecules in stone management or prophylaxis. Patients should be evaluated for the association with systemic pathologies. Prophylaxis: Personalized medicine and public health interventions are complementary to prevent stone recurrence. Personalized medicine addresses a small part of stone patients with a high risk of recurrence and systemic complications requiring specific dietary and pharmacological treatment to prevent stone recurrence and complications of associated systemic diseases. The more numerous subjects who form one or a few stones during their entire lifespan should be treated by modifications of diet and lifestyle. Primary prevention by public health interventions is advisable to reduce prevalence of stones in the general population. Renal stone formers at "high-risk" for recurrence need early diagnosis to start specific treatment. Stone analysis allows the identification of most "high-risk" patients forming non-calcium stones: infection stones (struvite), uric acid and urates, cystine and other rare stones (dihydroxyadenine, xanthine). Patients at "high-risk" forming calcium stones require a more difficult diagnosis by clinical and laboratory evaluation. Particularly, patients with cystinuria and primary hyperoxaluria should be actively searched. Future research: Application of Artificial Intelligence are promising for automated identification of ureteral stones on CT imaging, prediction of stone composition and 24-hour urinary risk factors by demographics and clinical parameters, assessment of stone composition by evaluation of endoscopic images and prediction of outcomes of stone treatments. The synergy between urologists, nephrologists, and scientists in basic kidney stone research will enhance the depth and breadth of investigations, leading to a more comprehensive understanding of kidney stone formation.
Patient Preferences and Priorities for the Design of an AKI Prevention Trial: Findings from a Consensus Workshop

Meghan J Elliott,Kirsten M Fiest,Shannan Love,Dale Birdsell,Maureena Loth,Heather Dumka,Benny Rana,Nusrat Shommu,Eleanor Benterud,Sarah Gil,Dilaram Acharya,Tyrone G Harrison,Neesh Pannu,Matthew T James

DOI: https://doi.org/10.34067/KID.0000000000000554

2024-08-15

Kidney360

Abstract:Introduction: High-quality clinical trials are needed to establish the efficacy and safety of novel therapies for acute kidney injury (AKI) prevention. In this consensus workshop, we identified patient and caregiver priorities for recruitment, intervention delivery, and outcomes of a clinical trial of cilastatin to prevent nephrotoxic AKI. Methods: We included adults with lived experience of AKI, chronic kidney disease, or risk factors for AKI (e.g., critical care hospitalization), and their caregivers. Using a modified nominal group technique approach, we conducted a series of hybrid in-person/virtual discussions covering 3 clinical trial topic areas: (1) consent and recruitment; (2) intervention delivery; and (3) trial outcomes. Participants voted on their top preferences in each topic area, and discussion transcripts were analyzed inductively using conventional content analysis. Results: Thirteen individuals (11 patients, 2 caregivers) participated in the workshop. For consent and recruitment, participants prioritized technology enabled pre-screening and involvement of family members in the consent process. For intervention delivery, participants prioritized measures to facilitate ease of intervention administration and return visits. For trial outcomes, participants identified kidney-related and other clinical outcomes (e.g., AKI, chronic kidney disease, cardiovascular events) as top priorities. Analysis of transcripts provided insight into care team and family involvement in trial-related decisions, implications of allocation to a placebo arm, and impact of participants' experiences of AKI and critical illness. Conclusion: Findings from our workshop will directly inform development of a clinical trial protocol of cilastatin for nephrotoxic AKI prevention and can assist others in patient-centered approaches to AKI trial design.
Perceived Significance of Engagement in Research Prioritization Among Chronic Kidney Disease Patients, Caregivers, and Health Care Professionals: A Qualitative Study

Meghan J. Elliott,Zahra Goodarzi,Joanna E. M. Sale,Linda A. Wilhelm,Andreas Laupacis,Brenda R. Hemmelgarn,Sharon E. Straus

DOI: https://doi.org/10.1177/2054358118807480

2018-01-01

Canadian Journal of Kidney Health and Disease

Abstract:BACKGROUND: Patients and other stakeholders are increasingly engaging as partners in research, although how they perceive such experiences, particularly over the long term, is not well understood.OBJECTIVE: To characterize how participants from a nondialysis chronic kidney disease (CKD) research priority-setting project conducted 2 years previously perceived the significance of their involvement.DESIGN: Qualitative descriptive study with semi-structured, individual interviews.SETTING: Participants resided across Canada.PARTICIPANTS: Eligible participants included stakeholders (ie, patients with nondialysis CKD, caregivers, health care professionals, and policy makers) who had taken part in a prior CKD research priority-setting project.MEASUREMENTS: We explored stakeholder experiences and perspectives on engagement in CKD research prioritization.METHODS: We purposively sampled across stakeholder roles and engagement types (ie, involvement in the priority-setting workshop, wiki online tool, and/or steering committee). All interviews were conducted by a single investigator by telephone or face-to-face, and audio-recordings were transcribed verbatim. The data were inductively coded and analyzed by 2 investigators using a thematic analysis approach.RESULTS: We conducted 23 interviews across stakeholder roles and engagement types. Participants appreciated the integration of distinct stakeholder communities of patients, researchers, and health care professionals that occurred through engagement in research priority setting. Their opportunity to interact with patients and others directly impacted by CKD outside of the clinical setting contributed to an enhanced understanding of the CKD lived experience and value of patient-oriented research. This interaction helped participants refine and refocus their commitment to patient-centered CKD care and research, characterized by enhanced knowledge and confidence (patients/caregivers), adaptations to existing clinical practices and policies (health care providers/policy makers), and subsequent research engagement.LIMITATIONS: The views of participants may not reflect those of individuals in other research or health care settings.CONCLUSIONS: Stakeholder engagement in nondialysis CKD research prioritization encouraged the integration of stakeholder communities, an appreciation of the CKD experience, and a refocusing of participants' commitment to research and care. Findings highlight considerations for future health research engaging stakeholders, particularly those living with CKD, as research partners.
Surgeon, and Institution Characteristics Associated Surgical Preferences in the Pediatric KIDney Stone (PKIDS) Care Improvement Network

Nicolas Fernandez,Jonathan S Ellison,Zi Wang,Jing Huang,David I Chu,Renea Sturm,Andrew A Stec,Ryan S. Hsi,Wayland Wu,Caleb Nelson,Christina Ching,Brian Augelli,Matt Lorenzo,Jing Bi-Karchin,Gregory E. Tasian

DOI: https://doi.org/10.1016/j.urology.2024.02.040

IF: 1.555

2024-03-09

Urology journal

Abstract:OBJECTIVE To reveal barriers and opportunities to implement evidence for the management of pediatric kidney stone disease, we determined surgeon and institutional factors associated with preferences for the type of surgical intervention for kidney and ureteral stones. METHODS We conducted a cross-sectional study of urologists participating in the Pediatric KIDney Stone Care Improvement Network (PKIDS) trial. Questionnaires ascertained strengths of urologists' preferences for types of surgery as well as characteristics of participating urologists and institutions. The outcome was the strength of preferences for ureteroscopy, shockwave lithotripsy, and percutaneous nephrolithotomy for four scenarios for which two alternative procedures are recommended by the AUA guidelines: A) 2 cm kidney stone, B) 9 mm proximal ureteral stone, C) 1.5 cm lower pole kidney stone, D) 1 cm non-lower pole kidney stone. Principal component analysis (PCA) was performed to identify unique clusters of factors that explain surgical preferences. RESULTS One hundred forty-eight urologists at 29 sites completed surveys. Stated preferences were highly skewed except for the choice between ureteroscopy and percutaneous nephrolithotomy for a 1.5 cm kidney stone. SWL ownership and local practice patters most frequently associated with the strength of surgeons' preferences for the type of surgery. PCA revealed that three clusters of stone, patient and heterogenous characteristics explained 30% of the variance in preferences. CONCLUSIONS There is wide variation in the strengths of preferences for surgical interventions supported by current guidelines that are partially explained by surgeon and institutional characteristics. These results reveal opportunities to develop strategies for guidelines that consider real-world drivers of care.

urology & nephrology
Randomized Controlled Trial of Ultrasonic Propulsion-Facilitated Clearance of Residual Kidney Stone Fragments vs Observation

Mathew D Sorensen,Barbrina Dunmire,Jeff Thiel,Bryan W Cunitz,Barbara H Burke,Branda J Levchak,Christina Popchoi,Arturo E Holmes,John C Kucewicz,M Kennedy Hall,Manjiri Dighe,Jessica C Dai,Fionnuala C Cormack,Ziyue Liu,Michael R Bailey,Michael P Porter,Jonathan D Harper

DOI: https://doi.org/10.1097/JU.0000000000004186

2024-08-15

Abstract:Purpose: Ultrasonic propulsion is an investigational procedure for awake patients. Our purpose was to evaluate whether ultrasonic propulsion to facilitate residual kidney stone fragment clearance reduced relapse. Materials and methods: This multicenter, prospective, open-label, randomized, controlled trial used single block randomization (1:1) without masking. Adults with residual fragments (individually ≤5 mm) were enrolled. Primary outcome was relapse as measured by stone growth, a stone-related urgent medical visit, or surgery by 5 years or study end. Secondary outcomes were fragment passage within 3 weeks and adverse events within 90 days. Cumulative incidence of relapse was estimated using the Kaplan-Meier method. Log-rank test was used to compare the treatment (ultrasonic propulsion) and control (observation) groups. Results: The trial was conducted from May 9, 2015, through April 6, 2024. Median follow-up (interquartile range) was 3.0 (1.8-3.2) years. The treatment group (n = 40) had longer time to relapse than the control group (n = 42; P < .003). The restricted mean time-to-relapse was 52% longer in the treatment group than in the control group (1530 ± 92 days vs 1009 ± 118 days), and the risk of relapse was lower (hazard ratio 0.30, 95% CI 0.13-0.68) with 8 of 40 and 21 of 42 participants, respectively, experiencing relapse. Omitting 3 participants not asked about passage, 24 treatment (63%) and 2 control (5%) participants passed fragments within 3 weeks of treatment. adverse events were mild, transient, and self-resolving, and were reported in 25 treated participants (63%) and 17 controls (40%). Conclusions: Ultrasonic propulsion reduced relapse and added minimal risk. Clinical trial registration no.: NCT02028559.
Developing Consensus-Based Priority Outcome Domains for Trials in Kidney Transplantation: A Multinational Delphi Survey With Patients, Caregivers, and Health Professionals

Bénédicte Sautenet,Allison Tong,Karine E Manera,Jeremy R Chapman,Anthony N Warrens,David Rosenbloom,Germaine Wong,John Gill,Klemens Budde,Lionel Rostaing,Lorna Marson,Michelle A Josephson,Peter P Reese,Timothy L Pruett,Camilla S Hanson,Donal O'Donoghue,Helen Tam-Tham,Jean-Michel Halimi,Jenny I Shen,John Kanellis,John D Scandling,Kirsten Howard,Martin Howell,Nick Cross,Nicole Evangelidis,Philip Masson,Rainer Oberbauer,Samuel Fung,Shilpa Jesudason,Simon Knight,Sreedhar Mandayam,Stephen P McDonald,Steve Chadban,Tasleem Rajan,Jonathan C Craig

DOI: https://doi.org/10.1097/TP.0000000000001776

Transplantation

Abstract:Background: Inconsistencies in outcome reporting and frequent omission of patient-centered outcomes can diminish the value of trials in treatment decision making. We identified critically important outcome domains in kidney transplantation based on the shared priorities of patients/caregivers and health professionals. Methods: In a 3-round Delphi survey, patients/caregivers and health professionals rated the importance of outcome domains for trials in kidney transplantation on a 9-point Likert scale and provided comments. During rounds 2 and 3, participants rerated the outcomes after reviewing their own score, the distribution of the respondents' scores, and comments. We calculated the median, mean, and proportion rating 7 to 9 (critically important), and analyzed comments thematically. Results: One thousand eighteen participants (461 [45%] patients/caregivers and 557 [55%] health professionals) from 79 countries completed round 1, and 779 (77%) completed round 3. The top 8 outcomes that met the consensus criteria in round 3 (mean, ≥7.5; median, ≥8; proportion, >85%) in both groups were graft loss, graft function, chronic rejection, acute rejection, mortality, infection, cancer (excluding skin), and cardiovascular disease. Compared with health professionals, patients/caregivers gave higher priority to 6 outcomes (mean difference of 0.5 or more): skin cancer, surgical complications, cognition, blood pressure, depression, and ability to work. We identified 5 themes: capacity to control and inevitability, personal relevance, debilitating repercussions, gaining awareness of risks, and addressing knowledge gaps. Conclusions: Graft complications and severe comorbidities were critically important for both stakeholder groups. These stakeholder-prioritized outcomes will inform the core outcome set to improve the consistency and relevance of trials in kidney transplantation.
Perceptions of Quality of Life and Pollution among China's Urban Middle Class: The Case of Smog in Tangshan

Xiaoyue Li,B. Tilt

DOI: https://doi.org/10.1017/S0305741017001382

2017-12-13

The China Quarterly

Abstract:Abstract After decades of rapid economic development, China is facing severe environmental problems. In particular, smog in urban areas has recently attracted a great deal of scientific and media attention both domestically and internationally. Our focus in this article is on public perceptions of smog in the northern city of Tangshan, which is routinely ranked as one of the urban areas with the worst air quality in the nation. In this article, we present the results of qualitative interviews and quantitative surveys with 341 urban residents. We examine how these residents perceive and weigh the importance of various aspects related to quality of life, including their experience with air pollution. Study participants considered environmental quality an issue of lower priority than many others; however, they surprisingly ranked it over economic concerns such as jobs and income. Their responses suggest that, for many urban residents, environmental problems like smog are fundamentally linked to basic quality of life concerns such as physical health and family well-being. We interpret our findings in the context of literature on the rise of China's middle class, the rise of environmental consciousness, and the role of gender in mediating perceptions of pollution and family health. We also consider the implications of these findings for the control and remediation of air pollution in China today. 摘要经过数十年迅猛的经济发展, 中国当下面临极其严重的环境问题。尤其是近些年中国的城市雾霾引起了国内外学者和媒体的广泛关注。这篇文章探讨了生活在中国北方城市唐山的人们对于雾霾污染的公众意识。在这篇文章中, 作者总结了定性访谈和 341 份城市调查问卷的分析结果, 介绍了唐山的城市居民如何认识和权衡生活质量相关的几个方面, 包括他们自身对于雾霾的经验和认知。被调查居民认为环境质量相较其他几项生活质量相关的方面并不在优先考虑之列, 然而却优先于经济考量,比如说比工作和家庭收入。被调查居民的回答反映出对于很多城市居民来讲, 环境问题很大程度上和对于最基本生活质量的忧虑息息相关, 包括身体健康以及家庭和睦。此文章引用了中国中产阶级的崛起, 环境意识的苏醒, 以及性别在影响环境相关的公众意识的作用为框架阐述研究成果, 同时作者认为此篇研究成果对于以后中国更好的控制和改善大气污染具有实践性的意义。
Patient and Caregiver Experiences and Attitudes about Their Involvement in Research in Chronic Kidney Disease

Talia Gutman,Ayano Kelly,Nicole Scholes-Robertson,Jonathan C Craig,Shilpanjali Jesudason,Allison Tong

DOI: https://doi.org/10.2215/CJN.05960521

Abstract:Background and objectives: Although patient and caregiver involvement in research is widely advocated to improve the relevance and uptake of study findings, barriers and uncertainties in achieving this goal remain. This study aimed to describe patient and caregiver experiences and perspectives of their previous involvement in research, to inform strategies to strengthen patient involvement in research. Design, setting, participants, & measurements: Semistructured interviews were conducted with 23 adult patients with CKD and caregivers who had previously been involved in research, from Australia, the United States, the United Kingdom, and Denmark. Transcripts were analyzed thematically. Results: We identified six themes: grappling with CKD diagnosis (overwhelmed by the burden of illness, silenced by stigma and shame, absence of advocacy, and awareness), bearing the responsibility for involvement (autonomy in their own care, forced to be proactive to access opportunities, infrastructural support to connect researchers and patients), battling big agendas (struggling in a system of disincentive, changing research culture, becoming equals), seeing the person behind the patient (harnessing broader knowledge, expertise, skills and interests, understanding patient needs, motivations for involvement), sensitivity to complexities of payment (accounting for individual circumstances, denoting value, enabling diverse involvement), and championing the patient voice (links to important stakeholders, drivers of innovation, responsibility to end users). Conclusions: The burden of CKD, limited opportunities, and power asymmetry between patients/caregivers and researchers were challenges to meaningful involvement in research. Building trust, awareness of opportunities, and recognizing the broad expertise and value of patients/caregivers, including and beyond their illness experience, may better support patient and caregiver involvement in research in CKD.
Patient-Centered Research and Outcomes in Cancer and Kidney Transplantation

Ellen Dobrijevic,Nicole Scholes-Robertson,Chandana Guha,Martin Howell,Allison Jauré,Germaine Wong,Anita van Zwieten

DOI: https://doi.org/10.1016/j.semnephrol.2024.151499

IF: 4.472

2024-03-28

Seminars in Nephrology

Abstract:Summary Cancer has been identified by kidney transplant recipients as a critically important outcome. The co-occurrence of cancer and kidney transplantation represents a complex intersection of diseases, symptoms, and competing priorities for treatments. Research that focuses on biochemical parameters and clinical events may not capture the priorities of patients. Patient-centered research can improve the relevance and efficiency of research and is particularly pertinent in the setting of cancer and kidney transplantation to facilitate shared decision-making in complex clinical situations. In addition, patient-reported outcomes can facilitate the assessment of patients' experiences, symptom burden, treatment side effects, and quality of life. This review discusses patient-centered research in the context of kidney transplantation and cancer, including consumer involvement in research and patient-centered outcomes and their measures and inclusion in core outcome sets.

urology & nephrology
Current Perspectives on Endourological Ex Vivo Stone Interventions in Kidney Transplantation: A Systematic Review

Hakan Bahadir Haberal,Senol Tonyali,Alberto Piana,Etienne Xavier Keller,Alba Sierra,Beatriz Bañuelos Marco,Lazaros Tzelves,Alessio Pecoraro,Francesco Esperto,Alicia López-Abad,Thomas Prudhomme,Riccardo Campi,Romain Boissier,Amelia Pietropaolo,Alberto Breda,Angelo Territo,EAU Young Academic Urologists (YAU) Kidney Transplantation and Endourology & Urolithiasis Working Groups

DOI: https://doi.org/10.1016/j.urology.2024.06.005

IF: 2.633

2024-06-13

Urology

Abstract:Objective: To conduct a systematic review (SR) of literature to assess the existing evidence concerning the success and complications of endourological ex vivo stone surgeries. Methods: Eligible studies for inclusion focused on investigating the success and/or complications related to endourological ex vivo surgeries in donors with nephrolithiasis. A SR was undertaken in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The search included databases of Web of Science, PubMed, and Scopus and only article in English were included. Studies published between 2002 and 2023 included in this SR. Results: After screening 1726 abstracts, this SR included 16 studies with a total of 209 patients. The mean stone size was 5.6 mm and majority of kidneys contained single stones, located in the lower calyx. After ex vivo endourological stone surgeries, the average stone-free rate was found to be 95.4%. The mean duration of ex vivo surgery was 17.3 minutes. Regarding intraoperative complications, two patients (1%) experienced mucosal injuries during pneumatic lithotripsy. As for postoperative complications, two patients (1%) experienced vascular complications. In terms of urological complications, hematuria was observed in 24 patients (11.5%), while one patient (0.5%) experienced clot formation in renal pelvis. Seven patients (3.3%) had urinary tract infections, and three patients (1.4%) developed urolithiasis during the follow-up. Additionally, one patient (0.5%) experienced complete occlusion of ureteroneocystostomy and required revision. Conclusion: Given the advancements in current technology and techniques, endourological ex vivo stone surgeries are increasingly recognized as an effective and safe option for donors with nephrolithiasis. Trial registration: This systematic review was registered under the protocol registration number CRD42024538384/PROSPERO.
Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey

Yeoungjee Cho,Gopala Rangan,Charlotte Logeman,Hyunjin Ryu,Benedicte Sautenet,Ronald D Perrone,Annie-Claire Nadeau-Fredette,Reem A Mustafa,Htay Htay,Michel Chonchol,Tess Harris,Talia Gutman,Jonathan C Craig,Albert C M Ong,Arlene Chapman,Curie Ahn,Helen Coolican,Juliana Tze-Wah Kao,Ron T Gansevoort,Vicente Torres,York Pei,David W Johnson,Andrea K Viecelli,Armando Teixeira-Pinto,Martin Howell,Angela Ju,Karine E Manera,Allison Tong

DOI: https://doi.org/10.1053/j.ajkd.2020.01.005

Abstract:Rationale & objective: Outcomes reported in trials involving patients with autosomal dominant polycystic kidney disease (ADPKD) are heterogeneous and rarely include patient-reported outcomes. We aimed to identify critically important consensus-based core outcome domains to be reported in trials in ADPKD. Study design: An international 2-round online Delphi survey was conducted in English, French, and Korean languages. Setting & participants: Patients/caregivers and health professionals completed a 9-point Likert scale (7-9 indicating critical importance) and a Best-Worst Scale. Analytical approach: The absolute and relative importance of outcomes were assessed. Comments were analyzed thematically. Results: 1,014 participants (603 [60%] patients/caregivers, 411 [40%] health professionals) from 56 countries completed round 1, and 713 (70%) completed round 2. The prioritized outcomes were kidney function (importance score, 8.6), end-stage kidney disease (8.6), death (7.9), blood pressure (7.9), kidney cyst size/growth (7.8), and cerebral aneurysm (7.7). Kidney cyst-related pain was the highest rated patient-reported outcome by both stakeholder groups. Seven themes explained the prioritization of outcomes: protecting life and health, directly encountering life-threatening and debilitating consequences, specificity to ADPKD, optimizing and extending quality of life, hidden suffering, destroying self-confidence, and lost opportunities. Limitations: Study design precluded involvement from those without access to internet or limited computer literacy. Conclusions: Kidney function, end-stage kidney disease, and death were the most important outcomes to patients, caregivers, and health professionals. Kidney cyst-related pain was the highest rated patient-reported outcome. Consistent reporting of these top prioritized outcomes may strengthen the value of trials in ADPKD for decision making.
Manipulating gene expression for the metabolic engineering of plants.

P. Lessard,H. Kulaveerasingam,G. York,A. Strong,A. Sinskey

DOI: https://doi.org/10.1006/MBEN.2001.0210

IF: 8.4

Metabolic Engineering

Abstract:Introducing and expressing foreign genes in plants present many technical challenges that are not encountered with microbial systems. This review addresses the variety of issues that must be considered and the variety of options that are available, in terms of choosing transformation systems and designing recombinant transgenes to ensure appropriate expression in plant cells. Tissue specificity and proper developmental regulation, as well as proper subcellular localization of products, must be dealt with for successful metabolic engineering in plants..
Preventive Pharmacologic Therapy for Kidney Stone Disease

Wilson Sui,Kevin Shee,Marshall Stoller

DOI: https://doi.org/10.1001/jamanetworkopen.2024.28927

2024-08-24

JAMA Network Open

Abstract:Urolithiasis is a disease of morbidity, rarely resulting in mortality, with increasing prevalence and high recurrence rates. 1 Considerable time and energy have been spent on identifying and implementing strategies to prevent subsequent kidney stone episodes. As most kidney stones are calcium based, thiazide diuretics have traditionally been used to decrease urinary calcium levels and thereby reduce recurrence rates. 2 Although a recent high-profile study, the Hydrochlorothiazide for Kidney Stone Recurrence Prevention [NOSTONE] trial, appears to argue against the use of diuretics given their negative findings, subanalyses from their own study suggest that higher doses of thiazides were associated with decreased kidney stone recurrence and more pronounced decreases in urinary calcium. 3 In their study, Hsi and colleagues 4 used a unique dataset built from linking patients between Litholink and Medicare. They found that higher thiazide dosages were associated with more pronounced reductions in urinary calcium levels and that the increased reduction in urinary calcium levels was associated with decreased kidney stone recurrence rates. The main findings of their study suggest that clinicians need to first identify patients with hypercalciuria and then aggressively treat them with thiazide diuretics to yield the most benefit in reducing kidney stone recurrence. The study by Hsi and colleagues 4 implies that patients should be aggressively screened for hypercalciuria and other urinary analyte abnormalities associated with kidney stone recurrence through tools such as the 24-hour urine test to identify those who may benefit the most from preventive pharmacologic intervention. The 24-hour urine test is cumbersome for patients to perform, and many clinicians have difficulties with interpretation due to the frequent presence of more than 1 abnormality, complex interactions between abnormalities, and borderline values. Frustratingly, patients who form kidney stones can have normal 24-hour urine collection results and those who do not form kidney stones can have abnormal 24-hour urine collection results. It is not surprising then that only 7% of patients at high risk undergo the 24-hour urine test 5 and that, among those with an initial abnormality, only 16% receive repeat testing within 6 months. 6 Dichotomizing patients into simply high and low risk of kidney stone formation may not be sensitive enough to stratify their risk of kidney stone recurrence. Finding more efficient methods to risk stratify patients for testing or iterating new testing modalities may thus be critical. Although urine calcium levels were measured, hypercalciuria was not an inclusion criteria in many of the randomized clinical trials evaluating thiazide diuretics, including NOSTONE. 2 ,3 However, thiazides demonstrated a protective effect in most of these trials, arguing for the utility of empiric therapy. These trials, however, are heterogeneous in terms of outcomes and adjunctive dietary management; therefore, the purported benefits of empiric therapy may be overstated. Among individuals who formed kidney stones in 3 prospective cohorts of health care professionals, the rates of hypercalciuria were 45% to 54%. 7 In comparison, 63% of participants in the NOSTONE trial had hypercalciuria, which may in part explain the contradictory findings. Directed preventive pharmacologic therapy may result in the most efficient reduction in recurrence of kidney stones, especially if higher dosages of medications are used. However, most clinicians likely prefer to start at low dosages and then titrate the dosage based on adverse effects and efficacy. In kidney stone disease, efficacy is ultimately defined by kidney stone events, which are often not a practical end point to use in practice, as symptomatic events are often separated by years or decades. Silent events, typically defined by radiographic changes, are also suboptimal as an end point because they require close, consistent monitoring with frequent radiation exposure that may have significant interobserver variability depending on the modality used. To titrate to the appropriate dosages suggested by Hsi and colleagues, 4 performing subsequent 24-hour urine testing for all patients to decide when to adjust dosing may be critical to success in modifying the disease course of recurrent nephrolithiasis. Published: August 22, 2024. doi:10.1001/jamanetworkopen.2024.28927 Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2024 Sui W et al. JAMA Network Open . Corresponding Author: Kevin Shee, MD, PhD, Department of Urology, University of California, San Francisco, 400 Parnassus Ave, A610, San Francisco, CA 94143 (Kevin.Shee@ucsf.edu). Conflic -Abstract Truncated-

medicine, general & internal
Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease

Simon A Carter,Charlotte Logeman,Martin Howell,Dan Cattran,Liz Lightstone,Arvind Bagga,Sean J Barbour,Jonathan Barratt,John Boletis,Dawn J Caster,Rosanna Coppo,Fernando C Fervenza,Jürgen Floege,Michelle A Hladunewich,Jonathan J Hogan,A Richard Kitching,Richard A Lafayette,Ana Malvar,Jai Radhakrishnan,Brad H Rovin,Nicole Scholes-Robertson,Hérnan Trimarchi,Hong Zhang,Yeoungjee Cho,Louese Dunn,Debbie S Gipson,Adrian Liew,Benedicte Sautenet,Andrea K Viecelli,David Harris,David W Johnson,Angela Yee-Moon Wang,Armando Teixeira-Pinto,Stephen I Alexander,Adam Martin,Allison Tong,Jonathan C Craig,Simon A. Carter,Sean J. Barbour,Dawn J. Caster,Fernando C. Fervenza,Michelle A. Hladunewich,Jonathan J. Hogan,A. Richard Kitching,Richard A. Lafayette,Brad H. Rovin,Debbie S. Gipson,Andrea K. Viecelli,David W. Johnson,Stephen I. Alexander,Jonathan C. Craig

DOI: https://doi.org/10.1016/j.kint.2021.04.027

IF: 19.6

2021-10-01

Kidney International

Abstract:Outcomes relevant to treatment decision-making are inconsistently reported in trials involving glomerular disease. Here, we sought to establish a consensus-derived set of critically important outcomes designed to be reported in all future trials by using an online, international two-round Delphi survey in English. To develop this, patients with glomerular disease, caregivers and health professionals aged 18 years and older rated the importance of outcomes using a Likert scale and a Best-Worst scale. The absolute and relative importance was assessed and comments were analyzed thematically. Of 1198 participants who completed Round 1, 734 were patients/caregivers while 464 were health care professionals from 59 countries. Of 700 participants that completed Round 2, 412 were patients/caregivers and 288 were health care professionals. Need for dialysis or transplant, kidney function, death, cardiovascular disease, remission-relapse and life participation were the most important outcomes to patients/caregivers and health professionals. Patients/caregivers rated patient-reported outcomes higher while health care professionals rated hospitalization, death and remission/relapse higher. Four themes explained the reasons for their priorities: confronting death and compounded suffering, focusing on specific targets in glomerular disease, preserving meaning in life, and fostering self-management. Thus, consistent reporting of these critically important outcomes in all trials involving glomerular disease is hoped to improve patient-centered decision-making.

urology & nephrology
Global Capacity for Clinical Research in Nephrology: a Survey by the International Society of Nephrology

Ikechi G. Okpechi,Mona Alrukhaimi,Gloria Ashuntantang,Ezequiel Bellorin‐Font,Mohammed Benghanem Gharbi,Branko Braam,John Feehally,David C.H. Harris,Vivekanand Jha,Kailash Jindal,David W. Johnson,Kamyar Kalantar‐Zadeh,Rümeyza Kazancıoğlu,Adeera Levin,Meaghan Lunney,Timothy O. Olanrewaju,Vlado Perkovic,Jeffrey Perl,Harun Ur Rashid,Éric Rondeau,Babatunde Lawal Salako,Arian Samimi,Laura Solá,Irma Tchokhonelidze,Natasha Wiebe,Chih‐Wei Yang,Feng Ye,Alexander Zemchenkov,Minghui Zhao,Aminu K. Bello

DOI: https://doi.org/10.1016/j.kisu.2017.10.012

IF: 6.083

2018-01-01

Kidney International Supplements

Abstract:Due to the worldwide rising prevalence of chronic kidney disease (CKD), there is a need to develop strategies through well-designed clinical studies to guide decision making and improve delivery of care to CKD patients. A cross-sectional survey was conducted based on the International Society of Nephrology Global Kidney Health Atlas data. For this study, the survey assessed the capacity of various countries and world regions in participating in and conducting kidney research. Availability of national funding for clinical trials was low (27%, n = 31), with the lowest figures obtained from Africa (7%, n = 2) and South Asia (0%), whereas high-income countries in North America and Europe had the highest participation in clinical trials. Overall, formal training to conduct clinical trials was inadequate for physicians (46%, n = 53) and even lower for nonphysicians, research assistants, and associates in clinical trials (34%, n = 39). There was also diminished availability of workforce and funding to conduct observational cohort studies in nephrology, and participation in highly specialized transplant trials was low in many regions. Overall, the availability of infrastructure (bio-banking and facilities for storage of clinical trial medications) was low, and it was lowest in low-income and lower-middle–income countries. Ethics approval for study conduct was mandatory in 91% (n = 106) of countries and regions, and 62% (n = 66) were reported to have institutional committees. Challenges with obtaining timely approval for a study were reported in 53% (n = 61) of regions but the challenges were similar across these regions. A potential limitation is the possibility of over-reporting or under-reporting due to social desirability bias. This study highlights some of the major challenges for participating in and conducting kidney research and offers suggestions for improving global kidney research.
Outcomes for clinical trials involving adults with chronic kidney disease: a multinational Delphi survey involving patients, caregivers and health professionals

Andrea Matus Gonzalez,Nicole Evangelidis,Martin Howell,Allison Jaure,Benedicte Sautenet,Magdalena Madero,Gloria Ashuntantang,Samaya Anumudu,Amelie Bernier-Jean,Louese Dunn,Yeoungjee Cho,Laura Cortes Sanabria,Ian H de Boer,Samuel Fung,Daniel Gallego,Chandana Guha,Andrew S Levey,Adeera Levin,Eduardo Lorca,Ikechi G Okpechi,Patrick Rossignol,Nicole Scholes-Robertson,Laura Sola,Armando Teixeira-Pinto,Tim Usherwood,Andrea K Viecelli,David C Wheeler,Katherine Widders,Martin Wilkie,Jonathan C Craig

DOI: https://doi.org/10.1093/ndt/gfae010

IF: 7.1857

2024-01-17

Nephrology Dialysis Transplantation

Abstract:ABSTRACT Background Many outcomes of high priority to patients and clinicians are infrequently and inconsistently reported across trials in chronic kidney disease (CKD), which generates research waste and limits evidence-informed decision making. We aimed to generate consensus among patients/caregivers and health professionals on critically important outcomes for trials in CKD prior to kidney failure and the need for kidney replacement therapy, and to describe the reasons for their choices. Methods This was an online two-round international Delphi survey. Adult patients with CKD (all stages and diagnoses), caregivers and health professionals who could read English, Spanish or French were eligible. Participants rated the importance of outcomes using a Likert scale (7–9 indicating critical importance) and a Best–Worst Scale. The scores for the two groups were assessed to determine absolute and relative importance. Comments were analysed thematically. Results In total, 1399 participants from 73 countries completed Round 1 of the Delphi survey, including 628 (45%) patients/caregivers and 771 (55%) health professionals. In Round 2, 790 participants (56% response rate) from 63 countries completed the survey including 383 (48%) patients/caregivers and 407 (52%) health professionals. The overall top five outcomes were: kidney function, need for dialysis/transplant, life participation, cardiovascular disease and death. In the final round, patients/caregivers indicated higher scores for most outcomes (17/22 outcomes), and health professionals gave higher priority to mortality, hospitalization and cardiovascular disease (mean difference >0.3). Consensus was based upon the two groups yielding median scores of ≥7 and mean scores >7, and the proportions of both groups rating the outcome as ‘critically important’ being >50%. Four themes reflected the reasons for their priorities: imminent threat of a health catastrophe, signifying diminishing capacities, ability to self-manage and cope, and tangible and direct consequences. Conclusion Across trials in CKD, the outcomes of highest priority to patients, caregivers and health professionals were kidney function, need for dialysis/transplant, life participation, cardiovascular disease and death.

urology & nephrology,transplantation

Hot-melt coating with lipid excipients.

Gaps in kidney stone disease management: From clinical theory to patient reality

Research Priority Setting in Kidney Disease: A Systematic Review

Research directions for kidney stone disease

Clinical Trial Considerations in Developing Treatments for Early Stages of Common, Chronic Kidney Diseases: A Scientific Workshop Cosponsored by the National Kidney Foundation and the US Food and Drug Administration

Management of urinary stones: state of the art and future perspectives by experts in stone disease

Patient Preferences and Priorities for the Design of an AKI Prevention Trial: Findings from a Consensus Workshop

Perceived Significance of Engagement in Research Prioritization Among Chronic Kidney Disease Patients, Caregivers, and Health Care Professionals: A Qualitative Study

Surgeon, and Institution Characteristics Associated Surgical Preferences in the Pediatric KIDney Stone (PKIDS) Care Improvement Network

Randomized Controlled Trial of Ultrasonic Propulsion-Facilitated Clearance of Residual Kidney Stone Fragments vs Observation

Developing Consensus-Based Priority Outcome Domains for Trials in Kidney Transplantation: A Multinational Delphi Survey With Patients, Caregivers, and Health Professionals

Perceptions of Quality of Life and Pollution among China's Urban Middle Class: The Case of Smog in Tangshan

Patient and Caregiver Experiences and Attitudes about Their Involvement in Research in Chronic Kidney Disease

Patient-Centered Research and Outcomes in Cancer and Kidney Transplantation

Current Perspectives on Endourological Ex Vivo Stone Interventions in Kidney Transplantation: A Systematic Review

Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey

Manipulating gene expression for the metabolic engineering of plants.

Preventive Pharmacologic Therapy for Kidney Stone Disease

Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease

Global Capacity for Clinical Research in Nephrology: a Survey by the International Society of Nephrology

Outcomes for clinical trials involving adults with chronic kidney disease: a multinational Delphi survey involving patients, caregivers and health professionals